People with diabetes, particularly severe diabetes, tend to lose less weight with GLP-1s than people without diabetes, so microdosing is less likely to be as effective, though their dose should only be increased as they tolerate it. George said that in her professional opinion, microdosing is a potential option for patients with smaller amounts of weight to lose or as a bridge to start, or wean off, regular GLP-1 medications
Recognizing the potential of semaglutide for weight management, researchers developed Wegovy, a higher-dose version of semaglutide approved in 2021 explicitly for chronic weight management in patients with obesity or overweight with at least one weight-related comorbidity
At higher doses, the first 4 weeks can produce a weight loss of around 5% of total body weight
Affordable and Convenient Options Oana Health also prioritizes affordability
BPC-157: Exceptional for gut health and tissue repair, it promotes healing, reduces inflammation, and enhances digestive function